Acurx Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: ACXP · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1736243
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-event
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K detailing a material agreement and equity sales. Keep an eye on developments.
AI Summary
On March 6, 2025, Acurx Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Acurx Pharmaceuticals, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- March 6, 2025 (date) — Earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Acurx Pharmaceuticals?
The filing states that Acurx Pharmaceuticals, Inc. entered into a material definitive agreement on March 6, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold by Acurx Pharmaceuticals?
The filing mentions 'Unregistered Sales of Equity Securities' as an item of disclosure, but does not specify the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 6, 2025.
What is the principal executive office address for Acurx Pharmaceuticals?
The principal executive offices of Acurx Pharmaceuticals are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the SIC code for Acurx Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Acurx Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).